Keywords: Pfizer, Rigel, Asthma drug candidate, R343, First-quarter 2011 results

Pfizer returns asthma drug candidate rights to Rigel Pharma; latter narrows losses

Article | 09 May 2011

Print This

As a result of global drugs behemoth Pfizer’s (NYSE: PFE) decision to exit R&D in the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in